EUVIMEDEUVIMED entdecken
Fallbericht

Enfortumab vedotin-induced bullous dermatitis

Robin Wang, Kristen Fernandez, Brandon Zelman, Jodi Speiser, Madhu Dahiya, David Eilers

Dermatology Online Journal · 2025

DOI: 10.5070/d331365370 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Dermatology Online Journal, 2025. Verfasst von Robin Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Loyola University Medical Center, Maywood, Illinois, United States. Robin.wang@luhs.org. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Drug Eruptions, Skin Diseases, Vesiculobullous, Immunoconjugates. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalDrug EruptionsSkin Diseases, VesiculobullousImmunoconjugatesUrinary Bladder NeoplasmsCarcinoma, Transitional CellAntineoplastic Agents, ImmunologicalHumansMaleAntibodies, Monoclonal, HumanizedAged

Substanzen

Antibodies, Monoclonal, HumanizedAntibodies, Monoclonalenfortumab vedotinpembrolizumabImmunoconjugatesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Dermatology, Loyola University Medical Center, Maywood, Illinois, United States. Robin.wang@luhs.org.

Zitieren

APA

Wang, R., Fernandez, K., Zelman, B., Speiser, J., Dahiya, M., & Eilers, D. (2025). Enfortumab vedotin-induced bullous dermatitis. Dermatology Online Journal. https://doi.org/10.5070/d331365370

Vancouver

Wang R, Fernandez K, Zelman B, Speiser J, Dahiya M, Eilers D. Enfortumab vedotin-induced bullous dermatitis. Dermatology Online Journal. 2025. doi:10.5070/d331365370

BibTeX
@article{Wang2025,
  author = {Wang, Robin and Fernandez, Kristen and Zelman, Brandon and Speiser, Jodi and Dahiya, Madhu and Eilers, David},
  title = {Enfortumab vedotin-induced bullous dermatitis},
  journal = {Dermatology Online Journal},
  year = {2025},
  doi = {10.5070/d331365370}
}
Kostenlos starten →